Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

181. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis

Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis Lv J, Ehteshami P, Sarnak MJ, Tighiouart H, Jun M, Ninomiya T, Foote C, Rodgers A, Zhang H, Wang H, Strippoli GF (...) , Perkovic V CRD summary This generally well-conducted review concluded that intensive blood pressure lowering regimens appeared to provide protection against kidney failure events in patients with chronic kidney disease, particularly among those with proteinuria; safety remained an uncertainty. The strength of evidence did not support strong conclusions on renal outcomes and the authors conclusions may be overly strong. Authors' objectives To assess the renal and cardiovascular effects of intensive

DARE.2013

182. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis

Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta (...) -analysis Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, Lok CE, Fitchett D, Tsuyuki RT CRD summary This review concluded that non-calcium-based phosphate binders were associated with a decreased risk of all-cause mortality compared with calcium-based phosphate binders in patients with chronic kidney disease. This was a generally well-conducted review but the conclusions seem overly strong. Authors' objectives To update a prior meta-analysis that compared the effect of calcium

DARE.2013

183. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline.

Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. DESCRIPTION: The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed clinical practice guidelines in 2012 to provide guidance on the evaluation, management, and treatment of chronic kidney disease (CKD) in adults and children who are not receiving renal replacement therapy. METHODS: The KDIGO CKD Guideline Development Work Group

Annals of Internal Medicine2013

184. Chronic kidney disease: global dimension and perspectives.

Chronic kidney disease: global dimension and perspectives. Chronic kidney disease is defined as a reduced glomerular filtration rate, increased urinary albumin excretion, or both, and is an increasing public health issue. Prevalence is estimated to be 8-16% worldwide. Complications include increased all-cause and cardiovascular mortality, kidney-disease progression, acute kidney injury, cognitive decline, anaemia, mineral and bone disorders, and fractures. Worldwide, diabetes (...) mellitus is the most common cause of chronic kidney disease, but in some regions other causes, such as herbal and environmental toxins, are more common. The poorest populations are at the highest risk. Screening and intervention can prevent chronic kidney disease, and where management strategies have been implemented the incidence of end-stage kidney disease has been reduced. Awareness of the disorder, however, remains low in many communities and among many physicians. Strategies to reduce burden and costs related

Lancet2013

185. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.

Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Since the first description of the association between chronic kidney disease and heart disease, many epidemiological studies have confirmed and extended this finding. As chronic kidney disease progresses, kidney-specific risk factors for cardiovascular events and disease come into play. As a result, the risk for cardiovascular disease is notably increased in individuals with chronic kidney disease. When (...) adjusted for traditional cardiovascular risk factors, impaired kidney function and raised concentrations of albumin in urine increase the risk of cardiovascular disease by two to four times. Yet, cardiovascular disease is frequently underdiagnosed and undertreated in patients with chronic kidney disease. This group of patients should, therefore, be acknowledged as having high cardiovascular risk that needs particular medical attention at an individual level. This view should be incorporated

Lancet2013

186. A Simple Tool to Predict End-Stage Renal Disease within 1 Year in Elderly Adults with Advanced Chronic Kidney Disease

A Simple Tool to Predict End-Stage Renal Disease within 1 Year in Elderly Adults with Advanced Chronic Kidney Disease 23617782 2013 05 15 2013 07 09 2016 10 19 1532-5415 61 5 2013 May Journal of the American Geriatrics Society J Am Geriatr Soc A simple tool to predict end-stage renal disease within 1 year in elderly adults with advanced chronic kidney disease. 762-8 10.1111/jgs.12223 To develop and validate a model to predict 1-year risk of end-stage renal disease (ESRD) in elderly subjects (...) with advanced chronic kidney disease (CKD). Retrospective. Veterans Affairs Medical Center. Individuals aged 65 and older with CKD with an estimated glomerular filtration rate (eGFR) less than 30 mL/min per 1.73 m(2) . The outcome was ESRD within 1 year of the index eGFR. Cox regression was used to develop a predictive model (Veterans Affairs (VA) risk score) that was validated in a separate cohort. Of the 1,866 participants in the developmental cohort, 77 developed ESRD. Risk factors for ESRD in the final

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro

187. Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease: Future Research Needs

Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease: Future Research Needs

Effective Health Care Program (AHRQ)2013

188. An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone

An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone 23051740 2012 12 28 2013 06 17 2016 12 15 1523-1755 83 1 2013 Jan Kidney international Kidney Int. An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney (...) ) with chronic kidney disease (CKD) defined as an eGFR <60 ml/min per 1.73 m(2). Blood pressure was lower in the combined therapy than in the high-dose ARB cohort in both groups with and without CKD. In patients with CKD, significantly more primary events (a composite of cardiovascular events and noncardiovascular death) occurred in the high-dose ARB group than in the combination group (30 vs. 16, respectively, hazard ratio 2.25). Significantly more cerebrovascular and more heart failure events occurred

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro

189. Meta-analysis: vitamin D compounds in chronic kidney disease.

Meta-analysis: vitamin D compounds in chronic kidney disease. Meta-analysis: vitamin D compound... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2007 ) Volume: 147 , Issue: 12 , Pages: 840-853 PubMed: Available from or Find this paper at: Abstract BACKGROUND: Vitamin D compounds are widely used to prevent and treat secondary hyperparathyroidism. PURPOSE: To determine whether vitamin D (...) therapy improves biochemical markers of mineral metabolism and cardiovascular and mortality outcomes in chronic kidney disease. DATA SOURCES: MEDLINE (January 1966 to July 2007), EMBASE (January 1980 to July 2007), and Cochrane databases were searched without language restriction. STUDY SELECTION: Randomized, controlled trials of vitamin D compounds in chronic kidney disease were identified. DATA EXTRACTION: Two authors independently extracted data. DATA SYNTHESIS: Seventy-six trials were identified

Annals of Internal Medicine2013

190. Ferumoxytol (Rienso) - Intravenous treatment of iron deficiency anaemia in adult patients with chronic kidney disease

Ferumoxytol (Rienso) - Intravenous treatment of iron deficiency anaemia in adult patients with chronic kidney disease

Scottish Medicines Consortium2013

191. Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis

Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis Cheng J, Zhang W, Zhang X, Li X, Chen J CRD summary The authors concluded that paricalcitol significantly reduced proteinuria and parathyroid hormone levels, with few adverse events, in patients with renal disease. Other than (...) the possibility of language bias, this was a generally well-conducted review, but there were few trials, with short follow-up, and the authors' conclusions should be considered to be tentative. Authors' objectives To assess the safety and efficacy of paricalcitol (a vitamin D compound) for patients with chronic kidney disease. Searching MEDLINE, EMBASE, and Cochrane Renal Group Trials Register were searched up to 2010; search terms were reported. Reference lists of identified articles were searched. Abstracts

DARE.2013

192. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis.

Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. 23343062 2013 01 24 2013 02 01 2015 11 19 1533-4406 368 4 2013 Jan 24 The New England journal of medicine N. Engl. J. Med. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. 320-32 10.1056/NEJMoa1203166 Peginesatide is a peptide-based erythropoiesis-stimulating agent (ESA) that may have therapeutic potential for anemia in patients with advanced chronic kidney disease. We (...) safety end point was 1.32 (95% CI, 0.97 to 1.81) for peginesatide relative to darbepoetin, with higher incidences of death, unstable angina, and arrhythmia with peginesatide. The efficacy of peginesatide (administered monthly) was similar to that of darbepoetin (administered every 2 weeks) in increasing and maintaining hemoglobin levels. However, cardiovascular events and mortality were increased with peginesatide in patients with chronic kidney disease who were not undergoing dialysis. (Funded

NEJM2013

193. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. 24206459 2013 12 26 2014 01 02 2016 12 15 1533-4406 369 26 2013 Dec 26 The New England journal of medicine N. Engl. J. Med. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. 2492-503 10.1056/NEJMoa1306033 Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2 (...) )-related factor 2 activators further reduce this risk is unknown. We randomly assigned 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease (estimated glomerular filtration rate [GFR], 15 to <30 ml per minute per 1.73 m(2) of body-surface area) to bardoxolone methyl, at a daily dose of 20 mg, or placebo. The primary composite outcome was end-stage renal disease (ESRD) or death from cardiovascular causes. The sponsor and the steering committee terminated the trial

NEJM2013 Full Text: Link to full Text with Trip Pro

194. Cohort study: Hypertensive disorders of pregnancy predict chronic kidney disease and end-stage renal disease

Cohort study: Hypertensive disorders of pregnancy predict chronic kidney disease and end-stage renal disease Hypertensive disorders of pregnancy predict chronic kidney disease and end-stage renal disease | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Hypertensive disorders of pregnancy predict chronic kidney disease and end-stage renal disease Article Text Aetiology Cohort study Hypertensive disorders of pregnancy predict chronic kidney disease and end-stage renal disease Ayub Akbari Statistics from Altmetric.com No Altmetric data available

Evidence-Based Medicine (Requires free registration)2013

195. KHA-CARI Guideline: Use of iron in chronic kidney disease patients

KHA-CARI Guideline: Use of iron in chronic kidney disease patients Original Article KHA-CARI Guideline: Use of iron in chronic kidney disease patients ROB MACGINLEY, 1 ROWAN WALKER 2 and MICHELLE IRVING 3 1 Deakin University Medical School, Geelong, 2 Department of Renal Medicine, Alfred Hospital, Melbourne, Victoria, and 3 Centre for Kidney Research, The Children’s Hospital at Westmead, Sydney, New South Wales, Australia Correspondence: Dr Rob MacGinley, Deakin University Medical School (...) , Pidgons Road, Waurn Ponds, Geelong, Vic. 3217, Australia. Email: rob.macginley@deakin.edu.au Accepted for publication 16 July 2013. Accepted manuscript online 23 July 2013. doi:10.1111/nep.12139 GUIDELINE RECOMMENDATIONS For: All chronic kidney disease (CKD) patients (CKD Stage 3–5; CKD Stage 5D (both peritoneal dialysis (PD) and haemodi- alysis (HD)). We recommend: a. That therapeutic iron be used to correct diagnosed iron de?ciency (1D). b. Parenteral iron (intravenous) is administered in prefer

KHA-CARI Guidelines2013

196. Chronic Kidney Disease - Cardiovascular effects of blood pressure lowering in patients with CKD

Chronic Kidney Disease - Cardiovascular effects of blood pressure lowering in patients with CKD ________________________________________________________________________________________________________________________ Cardiovascular Disease May 2013 Page 1 of 15 Cardiovascular effects of blood pressure lowering in patients with chronic kidney disease Date written: May 2013 Author: Hiddo J. Lambers Heerspink, Toshiharu Ninomiya, Rachel Huxley, Vlado Perkovic GUIDELINES Chronic kidney disease (...) not requiring dialysis a. We recommend that blood pressure targets in people with chronic kidney disease (CKD) should be determined on an individual basis taking into account a range of patient factors (1C) including baseline risk, albuminuria level, tolerability and starting blood pressure levels. b. We suggest that most people with CKD should be treated to similar targets as the general population, such that most blood pressure readings are below 140/90 (2D). We suggest that most blood pressure readings

KHA-CARI Guidelines2013

197. Chronic Kidney Disease - Cardiovascular disease: revascularisation

Chronic Kidney Disease - Cardiovascular disease: revascularisation ________________________________________________________________________________________________________________________ Cardiovascular Disease May 2013 Page 1 of 25 Cardiovascular disease: revascularisation Date written: May 2013 Author: Helen Pilmore GUIDELINES Chronic kidney disease not requiring dialysis a. We recommend that in patients with chronic kidney disease (CKD), end stage renal failure (ESRF) and after kidney (...) transplantation, that guidelines for revascularisation of the general population be adhered to (1D). UNGRADED SUGGESTIONS FOR CLINICAL CARE Patients with evidence of coronary artery disease should be referred to a cardiologist for expert opinion (ungraded) Physicians should be aware that revascularisation of coronary arteries with coronary artery bypass graft (CABG) and percutaneous intervention (PCI) is associated with greater mortality and morbidity in patients with chronic kidney disease (CKD) and those

KHA-CARI Guidelines2013

198. Chronic kidney disease (stage 4 or 5): management of hyperphosphatemia

Chronic kidney disease (stage 4 or 5): management of hyperphosphatemia Chronic kidne Chronic kidney disease (stage 4 or 5): y disease (stage 4 or 5): management of h management of hyperphosphataemia yperphosphataemia Clinical guideline Published: 13 March 2013 nice.org.uk/guidance/cg157 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline (...) inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Chronic kidney disease (stage 4 or 5): management of hyperphosphataemia (CG157) © NICE 2018. All rights reserved. Subject to Notice of rights (https

National Institute for Health and Clinical Excellence - Clinical Guidelines2013

199. Screening for early chronic kidney disease

Screening for early chronic kidney disease ________________________________________________________________________________________________________________________ Early Chronic Kidney Disease July 2012 Page 1 of 32 Screening for early chronic kidney disease Date written: July 2012 Author: Nigel Toussaint GUIDELINES a. We recommend screening for chronic kidney disease (CKD) as it is an effective strategy to allow earlier detection and management to reduce the increasing burden of CKD (1C). b (...) in Figure 1 (1D). UNGRADED SUGGESTIONS FOR CLINICAL CARE There are no ungraded statements. IMPLEMENTATION AND AUDIT 1. Primary practice audits of how many patients with one or more CKD risk factors receive annual evaluation of eGFR, albuminuria and blood pressure. 2. Conduct and evaluate a screening program with respect to the prevention or reduction of renal events (including end-stage kidney disease), cardiovascular events and mortality. BACKGROUND Chronic kidney disease (CKD) is a significant global

KHA-CARI Guidelines2013

200. Risk factors for early chronic kidney disease

Risk factors for early chronic kidney disease ________________________________________________________________________________________________________________________ Early Chronic Kidney Disease July 2012 Page 1 of 41 Risk factors for early chronic kidney disease Date written: July 2012 Author: David Johnson EVIDENCE SUMMARY a. The following risk factors are associated with an appreciable (20%-40%) risk of CKD: ? Obesity ? Hypertension ? Diabetes mellitus ? Cigarette smoking ? Established (...) recommendations. BACKGROUND Chronic kidney disease (CKD) is a major public health problem in Australia and throughout the world. Based on data from the AusDiab study [1], it is estimated that over 1.7 million Australian adults have at least moderately severe kidney failure, defined as an estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m 2 . This pernicious condition is often not associated with significant symptoms or urinary abnormalities and is unrecognized in 80-90% of cases [1-3]. CKD

KHA-CARI Guidelines2013